Cancer News and Research

Latest Cancer News and Research

Anti-epilepsy drug phenobarbital stunts neuronal growth

A brain study in infant rats demonstrates that the anti-epilepsy drug phenobarbital stunts neuronal growth, which could prompt new questions about using the first-line drug to treat epilepsy in human newborns.

11 May 2012

Study describes new compounds that inhibit PRMT1 enzyme

Scientists at The Scripps Research Institute have found the first chemical compounds that act to block an enzyme that has been linked to inflammatory conditions such as asthma and arthritis, as well as some inflammation-promoted cancers.

11 May 2012

'Packing problem' could have a solution for cancer treatment

A hidden facet of a math problem that goes back to Sanskrit scrolls has just been exposed by nanotechnology researchers at the University of Michigan and the University of Connecticut.

11 May 2012

Chromatin compaction required for proper embryonic stem cell differentiation

New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.

11 May 2012

Bacteria in digestive tracts compete against invading bacteria

From tiny villages in developing nations to suburban kitchens in the United States, dangerous strains of E. coli bacteria sicken millions of people each year - and kill untold numbers of children.

11 May 2012

Accelerated partial breast irradiation does not compromise survival

Using a concentrated, highly targeted dose of radiation to the breast has equally good results as irradiating the whole area, with no adverse effects on survival and a much better cosmetic outcome, Hungarian researchers have found.

11 May 2012

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the second wave of its LaunchTrends® Yervoy and Zelboraf report, in which 103 U.S.-based medical oncologists were surveyed about their current and expected treatment patterns in advanced melanoma.

11 May 2012

Less invasive procedure for heart disease

Doctors at Regions Hospital have begun performing a less invasive procedure for heart disease. Transcatheter aortic valve replacement (TAVR) was approved last November by the U.S. Food and Drug Administration for elderly patients who are too frail or too old for open heart surgery. The device is not approved for patients who are eligible for open heart surgery.

11 May 2012

Research roundup: Health providers' growing clout; The surprising bargain in Part D costs

The Growing Power Of Some Providers To Win Steep Payment Increases From Insurers Suggests Policy Remedies May Be Needed -- Concerns have grown that the consolidation of hospitals and physician groups has increased their ability to raise prices, which increases costs for insurers and patients.

11 May 2012

New discovery platform for antigen-specific monoclonal antibodies

Cell Signaling Technology, Inc. of Danvers, MA is pleased to announce the development of a new discovery platform for antigen-specific monoclonal antibodies.

From Cell Signaling Technology 11 May 2012

Arno AR-42 for neurofibromatosis type 2 receives EMA orphan-drug designation

Arno Therapeutics, Inc. announced today that its investigational compound known as AR-42 has been granted orphan-drug designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products for the treatment of neurofibromatosis type 2 (NF2).

11 May 2012

New combination therapy offers potential lifetime cure for advanced type 1 diabetes

City of Hope researchers developed a combination therapy to treat late-stage type 1 diabetes that appears to offer a potential lifetime cure for the disease without toxic side effects. The laboratory study is published in the May 9 edition of Science Translational Medicine.

11 May 2012

Citywide ban on public smoking can impact maternal and fetal health

A citywide ban on public smoking in Colorado led to significant decreases in maternal smoking and preterm births, providing the first evidence in the U.S. that such interventions can impact maternal and fetal health, according to an article in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

11 May 2012

African-Americans with scleroderma have more antibodies linked to severe complications

A new analysis finds that compared to Caucasians, African-Americans with systemic scleroderma have more antibodies in the blood that are linked to severe complications and an increased likelihood of death. They say this finding, published today in Arthritis & Rheumatism, suggests physicians can use these disease markers to screen and treat scleroderma patients proactively.

11 May 2012

NCSU scientists use light-activated molecules to turn gene expression on and off

Imagine being able to control genetic expression by flipping a light switch. Researchers at North Carolina State University are using light-activated molecules to turn gene expression on and off. Their method enables greater precision when studying gene function, and could lead to targeted therapies for diseases like cancer.

11 May 2012

CAPE arrests growth of prostate cancer tumors

Could it be that a remedy from thousands of years ago holds the secret to stopping prostate cancer? A newly published study furthers the exploration of caffeic acid phenethyl ester (CAPE) and its potential anticarcinogen and antioxidant properties. The demonstrated ability of CAPE to stop prostate cancer tumors from growing may soon have it earning a spot among other natural remedies for prostate cancer treatment.

11 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

RNP granules exit the nucleus via new budding mechanism akin to herpes-type viruses

New evidence published in Cell by Vivian Budnik, PhD, Melissa J. Moore, PhD, and colleagues at the University of Massachusetts Medical School, reveals a novel budding mechanism, similar to the process used by some viruses, capable of exporting large ribonucleoprotein particles from the nucleus to the cytoplasm.

11 May 2012

$EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL$

EC approves CTI’s Pixuvri to treat multiply relapsed or refractory aggressive NHL

Cell Therapeutics, Inc. today announced that it has received conditional marketing authorization from the European Commission for Pixuvri (pixantrone) as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

11 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012